NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
- Conditions
- Prostatic CancerProstatic Neoplasms
- Interventions
- Biological: ETBX-071; adenoviral PSA vaccineBiological: ETBX-061; adenoviral MUC1 vaccineBiological: ETBX-051; adenoviral brachyury vaccine
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT03481816
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT03478904
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
- Conditions
- Recurrent Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT03468985
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
Losartan for the Treatment of Pediatric NAFLD
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-10-21
- Target Recruit Count
- 83
- Registration Number
- NCT03467217
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern Univ-Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸University of Washington, Seattle, Washington, United States
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
- Conditions
- Pancreatic AdenocarcinomaPancreatic NeoplasmsPancreas CancerCancer of PancreasPancreatic Cancer
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT03451773
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
- Conditions
- B-Cell LymphomaAcute Lymphocytic LeukemiaB-Cell LeukemiaB-Non Hodgkin LymphomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, B CellAcute Lymphoid LeukemiaB-NHLAcute Lymphoblastic LeukemiaB-All
- Interventions
- Biological: CD19/CD22 CAR T-CellsProcedure: ApheresisOther: Anti-emeticDiagnostic Test: ECGDiagnostic Test: ECHODiagnostic Test: MRI BrainProcedure: Bone marrow biopsyDiagnostic Test: Cardiac MRI
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT03448393
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT03436732
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT03436745
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Biospecimen Procurement for Head and Neck Disorders
- Conditions
- Hearing DisorderHead and Neck NeoplasmsOral Mucosal DiseasePharyngeal NeoplasmLaryngeal Disease
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1000
- Registration Number
- NCT03429036
- Locations
- 🇺🇸
George Washington University Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins Hospital Bayview, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hospital Sibley Memorial Hospital, Washington, District of Columbia, United States
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 273
- Registration Number
- NCT03428945
- Locations
- 🇸🇪
Skane University Hospital, Malmö, Sweden
🇺🇸Joslin Center at SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Endocrinology Specialist / Greenville Health System, Greenville, South Carolina, United States